Future of Healthcare, Healthcare Analytics

Juno Medical Raises $12M Series A Led by NEXT VENTURES and Serena Ventures; Funding Will Fuel Juno's National Expansion

Juno Medical

Juno Medical, the modern doctor's office that's designed for the 99%, today announced $12 million in Series A funding co-led by Julian Eison, Managing Partner at NEXT VENTURES, and Serena Williams, Managing Partner at Serena Ventures. Juno’s comprehensive tech-enabled healthcare model is designed to meet the everyday healthcare needs of "the 99%,” with a specific focus on revitalizing neighborhoods across the United States and delivering a beautiful environment, transparent pricing, and exceptional care. The funding will support Juno’s continued development of its technology platform and expansion into new markets, including Atlanta, Georgia, Tulsa, Oklahoma, and Los Angeles, California.

Other notable participants include Vast Ventures, which led Juno’s seed round, Empire State Development’s New York Ventures, TXV Partners, Genius Guild, Gaingels, and previous investors Atento Capital and Humbition.

Juno’s team has unmatched healthcare, technology, and business expertise. Juno Founder and CEO Dr. Akili Hinson’s background spans medicine and business. He is a physician by training and former McKinsey & Company consultant with expertise in payment innovation, value-based care delivery, and digital transformation. Juno’s medical leadership team includes Chief Health Officer Dr. Aarti Agarwal, an internist and epidemiologist with expertise in global health and value-based care, as well as Juno’s two founding physicians, Dr. Shante Hinson, a rheumatologist and preventative health expert dedicated to bridging the healthcare gap in underserved communities, and Dr. Candice Fraser, an OB/GYN with over a decade of experience as a trusted guide in women's health.

Juno’s vision is to reimagine the future of healthcare by finally making exceptional, family-centered care accessible and affordable for the 99% all across the United States. At Juno, we’ve designed healthcare that people love by providing the highest quality care and incredible service in a beautiful environment that feels like a place to belong—all powered by modern technology. We are honored by the support of the thousands of patients who have trusted us with their care and our investors who believe in us — we could not be more excited to bring Juno to more neighborhoods and communities all across the country.”

Dr. Akili Hinson

Juno’s products and services are designed for the family’s “Chief Caregiver” by bringing the best of primary care, pediatrics, women's health, same-day care, and virtual care into one thoughtfully designed experience.

“It brings joy to my heart knowing Juno is on a mission to bring exceptional healthcare to cities and developing areas of our nation where suboptimal care, facilities, and services have been tolerated out of necessity for way too long," said Julian Eison, Managing Partner of NEXT VENTURES. “I believe Juno’s hybrid approach leveraging brick and mortar clinics paired with digital access is an enduring model that will serve as the fundamental basis to build community trust and outcomes to match. It’s an honor to have partnered with such an esteemed team, attacking one of the largest problems of our time.”

Juno accelerated the opening of its first location in the Harlem neighborhood of New York City to see patients in April 2020 when the COVID-19 pandemic devastated New York and many physician offices were closed. In addition to providing COVID testing and care to hundreds of residents, Juno continued to offer in-person preventive care during the pandemic which led to the identification of treatable cancers and previously undiagnosed chronic conditions in asymptomatic women and men — which may have been missed in the absence of the founding team’s commitment to serve.

“We are honored to partner with Juno to expand upon their inclusive, full-service healthcare home model where people from all backgrounds feel seen, heard and welcome,” said Serena Williams, Managing Partner of Serena Ventures. “There is a serious need to address equity issues in healthcare, mental health and wellness services that many communities face. Juno and its talented team have the vision, model and track record to disrupt the unacceptable status quo in healthcare.”

Juno’s approach and presence in underserved communities is part of the solution to a growing challenge of healthcare disparities that exist across the United States. A recent report from the Kaiser Family Foundation outlined race-based disparities in maternal and infant health and mortality. The markets in which Juno will expand have their own unique health care challenges. On November 1, Atlanta Medical Center closed its doors, leaving an already-strained healthcare system with one less option and exacerbating concerns about the future of safety net hospitals in the region and state. In North Tulsa, where Juno’s clinic will be located, residents have a life expectancy 13 years shorter than their neighbors in South Tulsa.

“Empire State Development’s New York Ventures exists to partner with promising startups that are working to solve the world’s most important challenges, and we are proud to support Juno Medical as they strive to provide exceptional healthcare to New Yorkers, especially in areas that are often overlooked or left behind,” said Hope Knight, President, CEO and Commissioner of Empire State Development. “Juno’s success in New York State is a road map for the future and a proven model for delivering quality, affordable healthcare for all.”

Unlike recent trends in concierge medicine and digital health, Juno’s model is designed to work with nearly all types of insurance—including commercial plans, Medicare and Medicaid—without initial barriers or exclusive membership fees. Juno is taking a different approach to meet the needs of busy households by offering additional plans that start at $20 per month per person or $50 per month per family that complement its core services with added conveniences like night and weekend appointments, savings, and unique events and experiences. Juno’s hybrid model includes both in-person options for patients and a robust e-health platform, which includes an app that allows patients to make appointments, manage care information, and keep in touch with their care team.

As part of its mission to create a healthier world, Juno will use this funding to expand into new markets and recruit the highest-caliber provider talent in Atlanta, Tulsa and Los Angeles. Juno’s new clinics will be located in the historic yet overlooked neighborhoods of East Atlanta, Greenwood (Tulsa), and Inglewood (Los Angeles). The funding will also support the continued expansion of Juno’s robust technology platform for both patients and healthcare providers—a critical component of Juno’s innovative model.

About Juno Medical  
Launched in April 2020, Juno Medical is a tech-enabled healthcare service provider designed for you and yours. The company offers exceptional hospitality, modern technology, and transparent prices that won't break the bank and brings the best of adult primary care, pediatrics, women's health, and same-day care into one thoughtful and beautifully designed place. 

Spotlight

Spotlight

Related News

Healthcare Analytics

SHL Medical partners with SteriPack Group to set up final assembly service

SHL Medical | January 24, 2024

SHL Medical, a world-leading solutions provider of advanced drug delivery systems and SteriPack Group, renowned global supplier of secondary packing and final assembly services to the pharmaceutical industry, enter a non-exclusive strategic partnership. Together, they aim to establish a pre-validated final assembly service at the SteriPack facility in Poland, enhancing the overall flexibility of supply chain strategies for their customers. In addition to SHL Medical's existing final assembly, labeling, and packaging­ services in the United States, this collaboration extends high-quality CMO options to Europe. Markus Puusepp, SHL Medical's Chief Growth Officer, expressed enthusiasm about the partnership, stating "This partnership is a significant addition to the Molly® platform value proposition. We share common values with SteriPack, from focus on the customer to a commitment to quality, making the decision to collaborate straightforward." Recognizing the importance of flexibility and time-to-market, especially in clinical production, the partnership with SteriPack will offer SHL Medical's customers highly flexible and personalized final assembly and packaging solutions. This is particularly beneficial for small batch handling in clinical supply and niche markets like rare diseases. Emphasizing the comprehensive capabilities of the Molly platform, SHL Medical aims to deliver right-sized solutions that ensure improved service, faster timelines, and a more streamlined supply chain for its diverse customer base. John Ward, SteriPack Group's VP Pharmaceutical Solutions commented "SteriPack Group looks forward to supporting SHL Medical and their customers in providing quality and flexible solutions to a fast- moving market. With an emphasis on creating service solutions designed around specific customer requirements, this partnership will make the process of working with the Molly® platform an easy decision." About SHL Medical As a world-leading solutions provider of advanced drug delivery systems, SHL Medical is the partner of choice for many leading pharma and biotech companies. Driven by its company purpose – Enabling Patients' Independence – SHL Medical offers patient-centric solutions for the design, development, and manufacturing of autoinjectors, pen injectors, as well as innovative specialty delivery systems for large-volume and high-viscosity formulations. It also offers final assembly, labeling, and packaging solutions for its drug delivery systems. In response to the rising trend in home therapy, SHL Medical has increased its developmental work in the digital healthcare sector to help improve the drug delivery ecosystem. Located across Switzerland, Taiwan, Sweden, and the US, SHL Medical's global team of experts collaborate seamlessly as one team in utilizing its comprehensive in-house manufacturing capabilities. Its solutions offer customization and optimization for each project while proactively weaving sustainability-driven measures into its designs and processes to contribute to a cleaner earth. About SteriPack Group SteriPack Group is a globally renowned contract packing and manufacturing organisation serving the pharmaceutical and medical device sectors respectively. With a strong emphasis on innovation, quality and compliance, SteriPack's services to the pharmaceutical industry include device design and development, final assembly, labelling, secondary packing, serialisation and aggregation of injectable formats including vials, pre-filled syringes, and autoinjectors. SteriPack's tailored customer-focused solutions make it an ideally suited supplier for small to medium-sized batch volumes required for a growing market of targeted therapies as well as clinical trials. Its proven capabilities in cleanroom assembly and labelling as well as secondary packing services for drug delivery systems and medical devices, combined with significant investment into growing cold chain storage capacity, have helped to make it a trusted partner to top global pharmaceutical companies.

Read More

Health Technology

BroadcastMed Launches New Platform for Vision Portfolio of Products

BroadcastMed | January 25, 2024

BroadcastMed, the leading healthcare information marketplace that provides trusted clinical content, powerful engagement, and industry insights to healthcare professionals (HCPs), medical institutions and manufacturers, service providers, and pharmaceutical companies, is thrilled to announce the evolution of its Vision portfolio. PentaVision, powered by BroadcastMed, released a new digital platform designed to elevate the user experience for healthcare and optical professionals. Driven by many of the industry's leading Optometry and Ophthalmology publications, the platform leverages an intricate network that spans across their entire suite of Vision brands. The architecture was designed to provide HCPs with vibrant, interactive content within personalized user experiences. Real-time industry data has been optimized, ensuring that HCPs remain informed of the latest developments, trends, and breakthroughs in the field. With a user-centric design, the platform enables HCPs to navigate effortlessly, thereby saving time and enhancing efficiency in accessing the most pertinent and valuable content. This dedication to convenience fosters continuous learning, collaboration, and professional growth. "We are delighted about the positive impact this enhanced network will have on our partners' ability to connect with HCPs in a meaningful way," said Lee Schweizer, Chief Digital Officer, BroadcastMed. "With optimized architecture for improved search visibility, a network-buying approach for advertisers, and plans for dynamic content in 2024, we're excited to offer enhanced benefits for both advertisers and healthcare providers." "The new Retinal Physician website offers faster navigation, improved content, and a streamlined interface. I think the changes will be appreciated by everyone!" said Peter K. Kaiser, MD, Professor of Ophthalmology, Chaney Family Endowed Chair in Ophthalmology Research. BroadcastMed, together with 424 Capital, a growth capital partner, acquired PentaVision in August of 2022 to expand its healthcare audience and secure high-quality content across 11 brands in vision care. PentaVision's media brands are among the most respected and read brands globally, and include Contact Lens Spectrum, Corneal Physician, Eyecare Business, Glaucoma Physician, New Retinal Physician, Optometric Management, Ophthalmology Management, Ophthalmic Professional, Presbyopia Physician, and Retinal Physician. Underlining its commitment to evolving content distribution, expanding multichannel reach, fostering engaging live events and streaming experiences, and providing insightful data to HCPs and supporting organizations, BroadcastMed is dedicated to advancing the field of healthcare. About BroadcastMed BroadcastMed is the leading healthcare information marketplace that provides trusted clinical content, powerful engagement and industry insights to healthcare professionals, medical institutions and manufacturers, service providers and pharmaceutical companies. The company's integrated platform of digital, event, and publication solutions helps drive better dialogue, connectivity, and outcomes for the healthcare community.

Read More

Health Technology

Beckman Coulter Unveils DxC 500 AU Chemistry Analyzer, Expanding Portfolio with Proven Six Sigma Performance

Beckman Coulter Diagnostics | January 30, 2024

Beckman Coulter Diagnostics, a clinical diagnostics leader, will unveil its new DxC 500 AU Chemistry Analyzer, an automated clinical chemistry analyzer, at Medlab Middle East in Dubai, taking place February 5-8, 2024. The DxC 500 AU Chemistry Analyzer is one of several recent Beckman Coulter solutions designed to address the complete needs of healthcare systems that are looking to complement central hub laboratories by advancing the technology and capabilities of satellite and independent hospital laboratories. "Healthcare systems around the world are strategically adopting hub-and-spoke models for better efficiency and healthcare access," said Kathleen Orland, Senior Vice President, Business Unit, General Manager, Chemistry and Immunoassay for Beckman Coulter Diagnostics. "Hub-and-spoke clinical laboratory models optimize resources to improve access to testing services and enhance overall standardization for quality testing and positive impact on inventory and cost management across a health system. The new DxC 500 AU Chemistry Analyzer advances capabilities of spoked labs with a broad menu of high-quality assays that deliver consistent, commutable results across Beckman Coulter's AU clinical chemistry systems, positively impacting clinical decision-making and patient outcomes." The DxC 500 AU Chemistry Analyzer features advanced automation technology, onboard guided workflows, and standardized reagents for use across healthcare networks. Its menu of more than 120 assays has been independently and objectively verified for high quality Six Sigma performance, supporting confidence in clinical results, reducing QC trouble shooting and lab operational costs. "Our Six Sigma assessment has shown that the DxC 500 AU analyzer easily exceeds the demands of the new, more stringent CLIA 2024 performance specifications," stated Sten Westgard, Director of Client Services and Technology for Westgard QC. The DxC 500 AU Chemistry Analyzer is for in vitro diagnostic use only. It is available throughout North America and the Middle East. Global commercial availability is planned for March 2024. About Beckman Coulter. Inc. A global leader in advanced diagnostics, Beckman Coulter has challenged convention to elevate the diagnostic laboratory's role in improving patient health for more than 80 years. Our mission is to Relentlessly Reimagine Healthcare, One Diagnosis at a Time – and we do this by applying the power of science, technology and the passion and creativity of our teams. Our diagnostic solutions are used in complex clinical testing, and are found in hospitals, reference laboratories and physician office settings around the globe. We exist to deliver smarter, faster diagnostic solutions that move the needle forward from what's now to what's next. We seek to accelerate care with an extensive clinical menu, scalable lab automation technologies, insightful clinical informatics, and optimize lab performance services. Headquartered in Brea, Calif., with more than 11,000 global team members, Beckman Coulter Diagnostics is proud to be part of Danaher. Danaher is a global science and technology leader. Together we combine our capabilities to accelerate the real-life impact of tomorrow's science and technology to improve human health. ©2024 Beckman Coulter. All rights reserved. Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries.

Read More